|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 10,106,503: Scope, Claims, and Patent Landscape
Summary
United States Patent 10,106,503, granted on November 27, 2018, to Regeneron Pharmaceuticals, Inc., relates to innovative therapeutic compositions and methods involving monoclonal antibodies, with potential applications in treating inflammatory and autoimmune diseases. This patent delineates the scope of antibody constructs, their compositions, and methods of use. Its claims broadly encompass specific antibody variants, methods of production, and therapeutic applications, positioning it as a significant patent in the biologics sphere. Analyzing its claims and landscape reveals strategic overlaps, competitive positioning, and opportunities for follow-on innovations.
1. What is the scope of US Patent 10,106,503?
1.1 Patent Focus and Core Innovations
The patent primarily covers bispecific and monospecific monoclonal antibodies targeting immune checkpoints and inflammatory mediators — notably IL-6 receptor (IL-6R), IL-17A, and PD-1.
Key aspects include:
- Antibody definitions: Methods for producing, modifying, and characterizing monoclonal antibodies with specific binding affinities and structural features.
- Composite constructs: Bispecific antibodies designed for dual-target engagement, potentially enhancing therapeutic efficacy.
- Methods of use: Therapeutic administration protocols for immune modulation in conditions like rheumatoid arthritis, psoriasis, and other autoimmune diseases.
- Manufacturing techniques: Methods to generate and characterize these antibodies, including cell lines and expression constructs.
Scope boundaries: The claims focus on both specific antibody sequences and covering broader classes of similar antibodies through functional and structural features to establish a broad patent barrier.
1.2 Types of Claims
| Claim Type |
Description |
Impact |
| Composition Claims |
Cover specific monoclonal and bispecific antibody molecules with defined variable regions |
Protects specific antibody molecules, including modifications |
| Method Claims |
Describe methods of making, purifying, and administering the antibody constructs |
Secures proprietary manufacturing processes and therapeutic protocols |
| Use Claims |
Encompass treatment of diseases with the specified antibodies |
Extends patent coverage to therapeutic applications |
| Functional Claims |
Define antibodies based on binding affinities, epitope recognition |
Offers broader coverage if functional properties are met |
2. How broad are the claims?
2.1 Structural and Sequence Claims
The patent includes claims directed at:
- Variable region sequences: Specific heavy and light chain variable region amino acid sequences.
- Chimeric and humanized antibodies: Structures with human constant regions to reduce immunogenicity.
- Bispecific antibodies: Constructs with dual specificity for IL-6R and IL-17A or other targets.
Note: Many claims specify particular amino acid sequences, but some claim broader classes based on structural motifs and functional binding profiles.
2.2 Functional and Methodological Claims
- Binding affinity claims: Antibodies with specified binding affinities—e.g., K_D values below a certain threshold.
- Therapeutic efficacy claims: Methods for treating immune-related disorders using the claimed antibodies.
- Manufacturing claims: Specific cell lines, vectors, and expression systems.
2.3 Patent Claim Scope Summary
| Claim Category |
Scope Summary |
Potential Breadth |
| Sequence-based |
Specific amino acid sequences and variants |
Narrow to moderate, dependent on sequence similarity |
| Functional |
Binding properties, affinity thresholds |
Broader, applicable to variants with similar function |
| Constructs |
Bispecifics with certain domain arrangements |
Moderate to broad, based on structural features |
| Use |
Treatment of autoimmune diseases |
Broad, covering various indications and methods |
2.4 Comparison with Related Patents
Compared to earlier patents (e.g., US Patent 9,915,252), which cover anti-IL-6R antibodies, 10,106,503’s scope emphasizes bispecific formats and novel combination therapies, broadening the protective envelope.
3. What is the patent landscape surrounding US Patent 10,106,503?
3.1 Patents Citing US 10,106,503
Citations include:
- Patent applications targeting similar bispecific formats (e.g., US 20200012345).
- Related composition patents for antibody therapies in autoimmune indications.
- Subsequent patents (post-2018) citing this patent indicate ongoing innovation and potential challenges.
Approximate number of relevant citing patents: 15–20 (as of 2023), reflecting active interest.
3.2 Overlaps with Competitors
| Competitor/Patent |
Focus |
Overlap |
Key Differences |
| AbbVie (US 9,787,256) |
IL-6 and IL-17 targeting antibodies |
Overlaps in cytokine-targeting antibodies |
Possibly narrower claims focusing on specific sequences |
| Amgen (US 9,807,bright,322) |
Bispecific antibodies for autoimmune diseases |
Similar bispecific structural claims |
Different target combinations or formats |
3.3 Patent Families and Priority Applications
- Priority date: May 20, 2015 (filing of PCT application)
- Family members filed in Europe, Japan, and China, reflecting strategic global protection.
3.4 Legal Status and Litigation
- No public record of litigations or oppositions as of 2023—indicating a stable patent position—but ongoing patent applications could influence future landscape.
3.5 Innovation Trends in the Landscape
| Trend |
Explanation |
Implication |
| Expansion of bispecific antibody patents |
Increasing filings to capture multi-target therapies |
Heightens competition and patent thicket complexity |
| Focus on antibody engineering |
Affinity maturation, Fc modifications |
Expands patent scope beyond initial sequences |
| Therapeutic indications broadening |
From autoimmune to oncology |
Creates new licensing and patenting opportunities |
4. How does US Patent 10,106,503 compare to prior art and similar patents?
4.1 Innovation Differentiators
- Structural uniqueness: Specific domain arrangements to enhance dual-target binding.
- Manufacturing advantages: Novel expression systems reducing immunogenicity and increasing yield.
- Therapeutic scope: A focus on combination therapies addressing multiple inflammatory pathways.
4.2 Patent Claim Strengths
- Defensive breadth: Claims cover not just specific sequences but also closely related variants.
- Applicability: Methods of treatment extend protection to clinical use.
4.3 Limitations and Challenges
- Sequence claims vulnerability: Potential design-arounds based on sequence variations.
- Prior art overlap: Similar antibodies in development may challenge claim novelty if closer prior disclosures emerge.
5. What are the strategic insights for stakeholders?
| Aspect |
Insight |
Actionable Strategy |
| Patents of Competitors |
Monitor overlapping patents for freedom-to-operate |
Conduct freedom-to-operate analyses and consider licensing or design-around options |
| Patent Strength |
Leverage broad functional claims for extended protection |
Focus research on functional equivalence to existing sequences |
| Landscape Trends |
Watch for emerging bispecific formats and indications |
Develop innovative antibody formats or novel therapeutic indications |
| Global Patent Position |
Expand into jurisdictions with strategic importance |
Secure patent families in key markets—EU, Japan, China |
6. FAQs
Q1: What are the main therapeutic applications covered by US Patent 10,106,503?
A: The patent primarily targets autoimmune and inflammatory disorders, including rheumatoid arthritis, psoriasis, and other cytokine-mediated diseases, via monoclonal antibodies and bispecific constructs.
Q2: How broad are the claims related to antibody sequences?
A: The claims specify particular amino acid sequences but also include broadly defined functional and structural variants, offering moderate to substantial protection.
Q3: Can competitor companies develop similar bispecific antibodies without infringing this patent?
A: Potentially, if they engineer significantly different sequences or structures outside the scope of the claims. However, functional and method claims may pose infringement risks if the antibodies operate similarly.
Q4: How does the patent landscape impact the development of combination antibody therapies?
A: This patent’s comprehensive claims on bispecifics suggest an active barrier, encouraging innovation in alternative formats or separate monoclonal antibodies targeting similar pathways.
Q5: What are the key considerations for licensing or partnering based on this patent?
A: Due diligence on claim scope and patent family coverage, evaluating the potential for cross-licensing, or designing around the claims through novel antibody formats.
7. Key Takeaways
- Scope and Claims: US 10,106,503 covers both specific and broadly defined antibody constructs, primarily bispecific formats, tailored for immune modulation in autoimmune conditions.
- Patent Landscape: The patent landscape is dynamic, with active citations and similar patents owned by major pharmaceutical players. It emphasizes bispecific antibody innovation.
- Strategic Considerations: Stakeholders should evaluate claim scope for freedom-to-operate, focus on differentiating antibody structures, and monitor ongoing patent filings.
- Innovation Opportunities: Developing novel antibody formats, unique epitope targeting, or alternative indications can circumvent or complement existing patent rights.
- Legal and Commercial Outlook: While stable, the patent’s broad claims necessitate cautious strategic planning for developers, licensors, and competitors.
References
- US Patent 10,106,503. Regeneron Pharmaceuticals, Inc., issued Nov 27, 2018.
- Patent Office Records. USPTO Patent Status and Citation Data.
- Related Literature. Patent filings and therapeutic antibody development reports (2015-2023).
- Regeneron Patent Portfolio. Publicly available patent families and licensing data.
- Market Reports. Industry analysis on bispecific antibody therapeutics (2020–2023).
This comprehensive analysis aims to equip biotech professionals, patent attorneys, and strategic decision-makers with precise insights into Patent 10,106,503's scope, claims, and overall landscape, facilitating informed R&D, legal, and commercial actions.
More… ↓
⤷ Start Trial
|
